25 May 2013
Keywords: crucell, per, c6-based, west, nile, vaccine, good
Article | 05 February 2007
Dutch biotechnology company Crucell NV has completed a Phase I safety study with the alum adjuvanted formulation of its whole ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
5 February 2007
7 February 2007
24 May 2013
© 2013 thepharmaletter.com